• Home
  • Store
    • Newsletter Subscriptions
    • Multimedia Subscriptions
    • Books
    • eBooks
    • ABPN SA Courses
  • CME Center
  • Multimedia
    • Podcast
    • Webinars
    • Blog
  • Newsletters
    • General Psychiatry
    • Child Psychiatry
    • Addiction Treatment
    • Hospital Psychiatry
    • Geriatric Psychiatry
  • Log In
  • Register
  • Welcome
  • Sign Out
  • Subscribe
Home » Oral vs Extended-Release Naltrexone for Opioid Use Disorder

Oral vs Extended-Release Naltrexone for Opioid Use Disorder

May 21, 2019
Jessica Goren, PharmD.
From The Carlat Addiction Treatment Report
Issue Links: Learning Objectives | Editorial Information
Jessica Goren, PharmD. Dr. Goren has disclosed that she has no relevant financial or other interests in any commercial companies pertaining to this educational activity.
Review of: Sullivan MA et al, Am J Psychiatry 2017;174(5):459–467

Extended-release (XR) naltrexone (Vivitrol) is FDA approved for opioid use disorder and has shown efficacy in several trials. It works best for patients who have already successfully detoxed from opioids and who are highly motivated to abstain. But what about oral naltrexone? While it is effective for alcohol use disorder, studies for opioid use disorder have shown limited utility. The reason is obvious—patients who are craving a fix can simply skip a dose of the naltrexone pill in order to achieve an opioid high, whereas the XR formulation forces a long delay, during which patients might reconsider their decision to use. Oddly enough, though, no study has been done comparing oral to XR naltrexone, until now.

Researchers randomized 60 adults with opioid use disorder (DSM-IV opioid dependence) to either oral or XR naltrexone. The study was a 6-month open-label trial, excluding people with unstable medical or psychiatric disorders, physical dependence on alcohol or sedative-hypnotics, treatment with opioids or psychotropic medications, and history of opioid overdose in the prior 3 years. The primary outcome measure was retention in treatment.

The study didn’t quite mimic real-world treatment, as study participants in both groups were asked to attend behavioral therapy sessions twice weekly, and those randomized to oral naltrexone either had to have a responsible adult as an involved medication monitor at home or go to the clinic 3 times weekly to have it administered. Vouchers were used to reinforce attendance. Participants were mostly white (63.3%), male (83.3%), and in their late 30s (mean age 39.5, SD = 11.1).

At the end of 6 months, the retention rate in the XR naltrexone group was significantly higher than the oral naltrexone group (57.1% and 28.1%, respectively). There was no significant difference in the percentage of ­opioid-positive urine tests between the groups, though that was not the primary outcome, and missed urine tests were not counted as positive.

Overall, the treatment was well tolerated, and most adverse events reflected opioid withdrawal and gradually improved.

CATR’s Take
The results confirm that XR naltrexone is more effective than oral naltrexone, even when rigorous strategies are used to ensure adherence with the oral formulation. We still recommend reserving XR naltrexone for patients who cannot be on buprenorphine or methadone—medications for which we have even more robust data.
Addiction Treatment
KEYWORDS addiction-treatment naltrexone opioid-use-disorder research-update
Jessica Goren, PharmD.

Mindfulness Therapy for Adult ADHD

More from this author
www.thecarlatreport.com
Issue Date: May 21, 2019
SUBSCRIBE NOW
Table Of Contents
CME Post-Test - Dual Diagnosis in Addiction Medicine, CATR, May/June 2019
Managing Substance-Related Agitation
Treating Co-Occurring Psychiatric Disorders
Cognitive Behavioral Therapy for Substance Use Disorders
Co-Occurring Addiction and PTSD
Oral vs Extended-Release Naltrexone for Opioid Use Disorder
Does Extended-Release Naltrexone Worsen Psychiatric Symptoms?
Featured Book
  • AUDFB1e_CoilBound_Graphic2_transparent_sm.png

    Treating Alcohol Use Disorder: A Fact Book (2023)

    All the tools and information needed to assess and treat your patients who are struggling with...
    READ MORE
Featured Video
  • therapist_canstockphoto9201097.jpg
    General Psychiatry

    Using SAMe In Clinical Practice with Garrett Rossi, MD

    Read More
Featured Podcast
  • Substance_Use_Sites.jpeg
    Addiction Treatment

    Supervised Drug Consumption Sites

    Once controversial, research clearly shows the benefit of these sites, and they have started opening in the United States.

    Listen now
Recommended
  • Approaches to Autism Intervention

    January 31, 2022
    canstockphoto2240982_child-bubbles_thumb.jpg
  • Currently Available Cannabis Products

    September 1, 2022
  • Interpreting Assessment Discrepancies from Multiple Sources

    October 17, 2022
    ChildAssessment.png
  • Approaches to Autism Intervention

    January 31, 2022
    canstockphoto2240982_child-bubbles_thumb.jpg
  • Currently Available Cannabis Products

    September 1, 2022
  • Interpreting Assessment Discrepancies from Multiple Sources

    October 17, 2022
    ChildAssessment.png
  • Approaches to Autism Intervention

    January 31, 2022
    canstockphoto2240982_child-bubbles_thumb.jpg
  • Currently Available Cannabis Products

    September 1, 2022
  • Interpreting Assessment Discrepancies from Multiple Sources

    October 17, 2022
    ChildAssessment.png

About

  • About Us
  • CME Center
  • FAQ
  • Contact Us

Shop Online

  • Newsletters
  • Multimedia Subscriptions
  • Books
  • eBooks
  • ABPN Self-Assessment Courses

Newsletters

  • The Carlat Psychiatry Report
  • The Carlat Child Psychiatry Report
  • The Carlat Addiction Treatment Report
  • The Carlat Hospital Psychiatry Report
  • The Carlat Geriatric Psychiatry Report

Contact

info@thecarlatreport.com

866-348-9279

PO Box 626, Newburyport MA 01950

Follow Us

Please see our Terms and Conditions, Privacy Policy, Subscription Agreement, Use of Cookies, and Hardware/Software Requirements to view our website.

© 2023 Carlat Publishing, LLC and Affiliates, All Rights Reserved.